Retatrutide
Investigational — Human trials in progressWhat it is
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) with published Phase 2 human data. Not approved anywhere.
Retatrutide is an investigational triple agonist (GIP, GLP-1 and glucagon receptors). Phase 2 human data has been published, but it is not approved anywhere and long-term safety is unestablished.
Research context
Studied in relation to:
- Weight management (trial-stage)
- Metabolic research
Points in its favour in the literature:
- Published Phase 2 human data
- Novel triple-agonist mechanism
- Strong reported trial weight loss
Caveats and unknowns:
- Investigational — not approved in any jurisdiction
- Long-term safety unestablished
- No monitored pharmacy equivalent
- Trial dosing not a self-use guide
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature. Once-weekly in the trials.
Reported half-lifelong-acting, once-weekly
Published clinical / research context (not instructions)Phase 2 trials explored ~1–12 mg once weekly with gradual escalation (trial-stage only).
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 10 mg vial + 2 mL → 5 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 5mg | RT5 |
| 10mg | RT10 |
| 15mg | RT15 |
| 20mg | RT20 |
| 30mg | RT30 |
| 40mg | RT40 |
| 50mg | RT50 |
| 60mg | RT60 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.